Topic: idiopathic pulmonary fibrosis
Lung Therapeutics has raised a $36 million series C round to take a treatment for a serious complication of pneumonia through phase 2 studies.
AstraZeneca tapped BenevolentAI to help bring artificial intelligence and machine learning to its drug discovery projects aimed at CKD and IPF.
The series C sets Galecto up to power into late-phase development despite Bristol-Myers Squibb passing up the chance to buy it out.
Roivant Sciences’ spinout machine keeps turning with the launch of the lung-focused Respivant Sciences, with tech and staff from Patara Pharma.
Pliant Therapeutics has raised a healthy $62 million series B to help fund its proof of concept tests across a range of scarring diseases.
Scientists have amassed evidence that the metformin's ability to target cell metabolism could help repair the lung.
Galecto Biotech hired Richard Marshall, head of fibrosis discovery at GlaxoSmithKline, to be CMO as it moves into late-phase trials of its IPF drug.
The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.
Following poor results from Roche and AstraZeneca, Sanofi says it is canning a phase 2 trial in idiopathic pulmonary fibrosis.
After a failed trial in May, AstraZeneca hoped tralokinumab could pass subpopulation tests and make it to the finish line, but it wasn’t meant to be.